Yazar "Beş, Cemal" seçeneğine göre listele

Listeleniyor 1 - 1 / 1
  • Küçük Resim
    Öğe
    Methodology of a new inflammatory arthritis registry: TReasure
    (Tubitak Scientific & Technical Research Council Turkey, 2018) Kalyoncu, Umut; Taşcılar, Etem Koray; Ertenli, Ali İhsan; Dalkılıç, Hüseyin Ediz; Beş, Cemal; Küçükşahin, Orhan; Kaşifoğlu, Timuçin; Alpay Kanitez, Nilüfer; Emmungil, Hakan; Kimyon, Gezmiş; Yaşar Bilge, Nazife Şule; Akar, Servet; Atagündüz, Mehmet Pamir; Koca, Süleyman Serdar; Ateş, Aşkın; Yazısız, Veli; Terzioğlu, Ender; Ersözlü, Emine Duygu; Tufan, Müge Aydın; Çınar, Muhammet; Mercan, Rıdvan; Şahin, Ali; Erten, Şükran; Pehlivan, Yavuz; Yılmaz, Sedat; Keleşoğlu Dinçer, Ayşe Bahar; Gerçik, Onay; Coşkun, Belkıs Nihan; Yağız, Burcu; Kaymaz Tahra, Sema; Aksoy, Aysun; Karadağ, Ömer; Kılıç, Levent; Kiraz, Sedat
    Background/aim: The TReasure registry, created in 2017, is an observational multicenter cohort that includes inflammatory arthritis patients. This article reviews the methodology and objectives of the TReasure registry established to collect data from rheumatoid arthritis (RA) and spondyloarthritis (SpA) patients. Methodology: Fifteen rheumatology centers in Turkey will contribute data to the TReasure database. The actual proprietor of the database is the Hacettepe Rheumatology Association (HRD) and Hacettepe Financial Enterprises. Pharmaceutical companies that operate in Turkey (in alphabetical or er), Abbvie, Amgen, BMS, Celltrion Healthcare, Novartis, Pfizer, Roche, and UCB, support the TReasure registry. TReasure is a web-based database to which users connect through a URL (https://www.trials-network.org/treasure) with their unique identifier and passwords provided for data entry and access. TReasure records demographic and clinical features, comorbidities, radiology and laboratory results, measures of disease activity, and treatment data. Discussion: TReasure will provide us with various types of data, such as a cross-sectional view of the current nationwide status of the patients currently receiving these treatments, and retrospective data as much as allowed by the participating centers' records. Finally, a high-quality prospective dataset will be built over the ensuing years from patients with a new diagnosis of RA or SpA.